Initiating Coverage of Sinopharm with Narrow Moat Rating, FVE of HKD 36 Per Share
We initiate coverage of Sinopharm Group Co (H) (1099 HK) with a narrow moat rating and a fair value estimate of HKD 36 per share, implying a 2018...
333 Views
China Drug Distribution: More "Two Invoice" Changes
The restructuring of China's drug distribution industry continues with Baiyunshan Phrmcl Hldgs Co Ltd (874 HK)'s pending buyout of Walgreens Boots...
592 Views
Walgreens Invests in Sinopharm Retail Arm
Walgreens Boots Alliance Inc (WBA US) has agreed to buy a 40% stake in Sinopharm Group Co H (1099 HK) 's Guoda Drug Store chain (held by...
697 Views
Shanghai Pharma Gets Cardinal Health Deal
Shanghai Pharmaceuticals H (2607 HK) has agreed to acquire Cardinal Health Inc (CAH US) 's China distribution business for US$1.2 billion (subject...
644 Views
Deceleration Likely Driving Cardinal Valuation
One of the questions posed during the discussion of Cardinal Health Inc (CAH US) 's plan to sell its China drug distribution business was the...
499 Views